Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Long-Term Deferred Tax (2023 - 2024)

Historic Long-Term Deferred Tax for Nuvation Bio (NUVB) over the last 2 years, with Q4 2024 value amounting to $242.6 million.

  • Nuvation Bio's Long-Term Deferred Tax rose 13921.13% to $242.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $242.6 million, marking a year-over-year increase of 13921.13%. This contributed to the annual value of $242.6 million for FY2024, which is 13921.13% up from last year.
  • Nuvation Bio's Long-Term Deferred Tax amounted to $242.6 million in Q4 2024, which was up 13921.13% from $101.4 million recorded in Q4 2023.
  • Nuvation Bio's 5-year Long-Term Deferred Tax high stood at $242.6 million for Q4 2024, and its period low was $101.4 million during Q4 2023.